Resumen de acción ORTX
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Orchard Therapeutics plc
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.70 |
| 52 Week High | US$16.72 |
| 52 Week Low | US$4.24 |
| Beta | 0.55 |
| 1 Month Change | 1.71% |
| 3 Month Change | 4.57% |
| 1 Year Change | 188.88% |
| 3 Year Change | -70.28% |
| 5 Year Change | -86.41% |
| Change since IPO | -88.07% |
Noticias y actualizaciones recientes
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Rentabilidad de los accionistas
| ORTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | 1.3% | 3.3% |
| 1Y | 188.9% | 3.0% | 25.0% |
Rentabilidad vs. Industria: ORTX superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: ORTX superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| ORTX volatility | |
|---|---|
| ORTX Average Weekly Movement | 0.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ORTX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ORTX ha disminuido de 16% a 1% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 166 | Bobby Gaspar | www.orchard-tx.com |
Resumen de fundamentos de Orchard Therapeutics plc
| Estadísticas fundamentales de ORTX | |
|---|---|
| Capitalización bursátil | US$380.12m |
| Beneficios(TTM) | -US$72.92m |
| Ingresos (TTM) | US$21.84m |
17.4x
Ratio precio-ventas (PS)-5.2x
Ratio precio-beneficio (PE)¿Está ORTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ORTX | |
|---|---|
| Ingresos | US$21.84m |
| Coste de los ingresos | US$79.52m |
| Beneficio bruto | -US$57.68m |
| Otros gastos | US$15.24m |
| Beneficios | -US$72.92m |
Últimos beneficios comunicados
Sep 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.20 |
| Margen bruto | -264.11% |
| Margen de beneficio neto | -333.90% |
| Ratio deuda/patrimonio | 31.9% |
¿Cómo se ha desempeñado ORTX a largo plazo?
Ver rendimiento histórico y comparativa